Regeneron Reports Second Quarter 2018 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Regeneron Reports Second Quarter 2018 Financial and Operating Results
August 2, 2018 3:51 PM EDT
Cowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
August 2, 2018 11:48 AM EDT
Evercore ISI raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $405.00) while maintaining a Outperform rating.
Analyst Josh Schimer noted strong performance across the board for product revenue and expenses. Dupixent/OUS Eylea were strongest spots.
...
More
August 2, 2018 6:38 AM EDT
Regeneron (NASDAQ: REGN) reported Q2 EPS of $5.45, $0.75 better than the analyst estimate of $4.70. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.56 billion.
Second quarter 2018 GAAP net income per diluted share increased by 44% to $4.82 versus second quarter 2017 and...
More
